Simultaneous Carcinomas of the Breast and Ovary: Utility of Pax-8, WT-1, and GATA3 for Distinguishing Independent Primary Tumors from Metastases

Breast carcinomas rarely metastasize to the ovary and are even more rarely present clinically as primary ovarian tumors. However, patients with breast cancer not infrequently develop independent primary ovarian carcinomas. In these cases, distinction between independent primaries and metastatic tumors is crucial. Several comparative immunohistochemical studies have been reported, but few included significant clinicopathologic data and none investigated cases of ovarian and breast carcinomas from the same patients. In this study, we compared 18 cases of patients with bona fide independent breast and ovarian carcinomas (15 high-grade serous and 3 clear cell carcinomas), with 9 cases of patients with known mammary carcinomas (7 lobular and 2 ductal carcinomas) metastatic to the ovary. Immunohistochemical stains for Pax-8, WT-1, and GATA3 were carried out on tissue microarrays (TMA). Most primary ovarian carcinomas were larger than the metastatic tumors (P=0.001) and were diagnosed at an advanced stage. All primary ovarian tumors showed marked nuclear pleomorphism, whereas only 2 metastatic breast carcinomas had Grade 3 nuclei (P=0.000). The vast majority of ovarian metastases (7/9) showed the typical pattern of lobular breast carcinoma. Pax-8 and WT-1 expression were found in 16 of 18 (88%) and 13 of 18 (72%) primary ovarian carcinomas, respectively. In contrast, all primary ovarian carcinomas were negative for GATA3. The 2 Pax-8-negative ovarian carcinomas were also negative for WT-1. With the exception of 3 triple-negative carcinomas, all primary breast carcinomas were positive for GATA3. All metastatic breast carcinomas were positive for GATA3 and negative for Pax-8. WT-1 expression was seen in only 1 of 9 metastatic breast carcinomas (11%). Patients with ovarian metastases had worse prognosis than patients with independent breast and ovarian carcinomas (P=0.000). Pax-8, WT-1, and GATA3 immunoreactions are useful in the distinction between independent primaries and metastatic mammary carcinomas to the ovary in the light of clinicopathologic findings.

[1]  E. Trimble,et al.  Abdominal carcinomatosis in women with a history of breast cancer. , 2005, Gynecologic oncology.

[2]  P. Prior,et al.  Multiple primary cancers of the breast and ovary. , 1981, British Journal of Cancer.

[3]  M. Merino,et al.  Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary. , 1991, Human pathology.

[4]  Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? , 2008, Human pathology.

[5]  Markku Miettinen,et al.  GATA3: A Multispecific But Potentially Useful Marker in Surgical Pathology A Systematic Analysis of 2500 Epithelial and Nonepithelial Tumors , 2014, The American journal of surgical pathology.

[6]  Joshy George,et al.  Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.

[7]  R. Buller,et al.  Frequency of BRCA1 dysfunction in ovarian cancer. , 2002, Journal of the National Cancer Institute.

[8]  R. Buller,et al.  Inactivation of BRCA1 and BRCA2 in ovarian cancer. , 2002, Journal of the National Cancer Institute.

[9]  M. Zahurak,et al.  Ovarian Malignancy in Breast Cancer Patients With an Adnexal Mass , 2005, Obstetrics and gynecology.

[10]  E. Salamalekis,et al.  Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results. , 2006, Anticancer research.

[11]  R. Barakat,et al.  Ovarian disease in women with breast cancer , 1994, Obstetrics and gynecology.

[12]  P. Nederlof,et al.  High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. , 2009, Cancer research.

[13]  B. Silver,et al.  Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. , 2002, International journal of radiation oncology, biology, physics.

[14]  J. Higgins,et al.  Expression of the Urothelial Differentiation Markers GATA3 and Placental S100 (S100P) in Female Genital Tract Transitional Cell Proliferations , 2009, The American journal of surgical pathology.

[15]  A. Vincent-Salomon,et al.  High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. , 2009, Cancer research.

[16]  S. Robboy,et al.  Breast carcinoma masquerading as primary ovarian neoplasm , 1981, Cancer.

[17]  S. Kobayashi.  Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance , 2008, Breast cancer.

[18]  A. Ashworth,et al.  Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers , 2009, Clinical Cancer Research.

[19]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[20]  Luis Chiriboga,et al.  Expression of Pax8 as a Useful Marker in Distinguishing Ovarian Carcinomas From Mammary Carcinomas , 2008, The American journal of surgical pathology.

[21]  P. V. van Diest,et al.  Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. , 1999, Journal of clinical pathology.

[22]  E. Venkatraman,et al.  Breast cancer metastatic to abdomen and pelvis: role of surgical resection. , 2003, Gynecologic oncology.

[23]  Marc K Halushka,et al.  GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. , 2013, Human pathology.

[24]  P. Hall,et al.  Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study , 2002, The Lancet.

[25]  G. Pinkus,et al.  WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. , 2002, American journal of clinical pathology.

[26]  E. Darai,et al.  Ovarian metastases from breast cancer , 2010, Cancer.

[27]  L. Norton,et al.  Expression of WT1, CA 125, and GCDFP-15 as Useful Markers in the Differential Diagnosis of Primary Ovarian Carcinomas Versus Metastatic Breast Cancer to the Ovary , 2005, The American journal of surgical pathology.